GlassScriptPhysician profile
Frances J Peredo
NPI 1952728255
$19,346.43
in general payments reported to CMS, 2019-2025
13 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.15 · 2022: $147 · 2023: $1,216 · 2024: $1,656 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $16K · Food and Beverage: $3,623 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $15,523.58 |
| Food and Beverage | $3,622.56 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $15,843.05 | 2024-2025 | |
| Abbott Laboratories | $1,076.36 | 2022-2024 | Cardiomems |
| Revance Therapeutics, INC. | $830.44 | 2024-2025 | Daxxify |
| Abbvie INC. | $515.50 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $301.00 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.39 | 2023-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Galderma Laboratories, L.P. | $261.18 | 2024-2025 | |
| Amgen INC. | $100.44 | 2023-2024 | Repatha |
| Abiomed | $42.24 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $33.60 | 2023 | Farxiga |
| Baxter Healthcare | $21.98 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $21.63 | 2023 | |
| Lantheus Medical Imaging, INC. | $21.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Peredo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.